Aptose Biosciences to Present at Canaccord Genuity 39th Annual Growth Conference
July 30, 2019 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
July 16, 2019 07:05 ET
|
Aptose Biosciences, Inc.
– CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – APTO-253 MYC inhibitor being developed for the...
Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association
June 14, 2019 07:00 ET
|
Aptose Biosciences, Inc.
– CG-806 safely and durably suppressed tumor growth in preclinical models – SAN DIEGO and TORONTO, June 14, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ:...
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
June 04, 2019 16:02 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 04, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Appoints Jotin Marango, M.D., Ph.D. as Chief Business Officer
June 03, 2019 09:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the...
Aptose Announces Closing of Public Offering of Common Shares
June 03, 2019 08:38 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced...
Aptose to Present at the Jefferies 2019 Healthcare Conference
May 31, 2019 08:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 31, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target the...
Aptose Announces Pricing of Public Offering of Common Shares
May 30, 2019 09:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 30, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced...
Aptose Announces Proposed Public Offering of Common Shares
May 29, 2019 16:22 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 29, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public...
Aptose Biosciences Establishes New At-The-Market Facility
May 24, 2019 17:43 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...